Details

Autor(en) / Beteiligte

• Najima, Yuho
• Sadato, Daichi
• Harada, Yuka
• Oboki, Keisuke
• Hirama, Chizuko
• Toya, Takashi
• Doki, Noriko
• Haraguchi, Kyoko
• Yoshifuji, Kota
• Akiyama, Megumi
• Inamoto, Kyoko
• Igarashi, Aiko
• Kobayashi, Takeshi
• Kakihana, Kazuhiko
• Okuyama, Yoshiki
• Sakamaki, Hisashi
• Harada, Hironori
• Ohashi, Kazuteru

Titel

Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT

Ist Teil von

• Bone marrow transplantation (Basingstoke), 2021-02, Vol.56 (2), p.334-346

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Quelle

Elektronische Zeitschriftenbibliothek (Open access)

Beschreibungen/Notizen

• Outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in nonremission acute myeloid leukemia (AML) are dismal [2-year overall survival (OS): 20-30%]. Though several risk classifications have been used, some factors are unavailable until the start of conditioning or transplantation. We analyzed prognostic gene mutations by targeted next-generation sequencing to identify predisposing factors for predicting OS at 1 month before transplantation. We enrolled 120 patients with nonremission AML who underwent first allo-HSCT between 2005 and 2018. Mutations were found in 98 patients; frequently mutated genes were FLT3-ITD, TP53, RUNX1, and WT1. TP53 mutation was detected in 21 patients and was the only predictor of poor OS. Multivariate analysis using Cox regression hazard model revealed primary AML, monosomal karyotype (MK), and TP53 mutation as independent factors for predicting poor OS. Based on these, patients were stratified into three groups. The low-risk group included patients with prior myeloid disorder without MK (n = 26). Among the rest, patients with TP53 mutation were assigned to the high-risk group (n = 19) and the rest into the intermediate-risk group (n = 75). Two-year OS in low-, intermediate-, and high-risk groups differed significantly (50.0%, 24.9%, and 0%, respectively). This suggests that the indication of allo-HSCT should be carefully judged for high-risk patients.